MediWound Ltd. (MDWD)
| Market Cap | 197.92M +4.5% |
| Revenue (ttm) | 14.48M -24.6% |
| Net Income | -26.11M |
| EPS | -2.19 |
| Shares Out | 12.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,699 |
| Open | 15.40 |
| Previous Close | 16.68 |
| Day's Range | 15.40 - 15.40 |
| 52-Week Range | 14.90 - 22.51 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 31.33 (+103.44%) |
| Earnings Date | May 27, 2026 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other ... [Read more]
Financial Performance
In 2025, MediWound's revenue was $16.96 million, a decrease of -16.14% compared to the previous year's $20.22 million. Losses were -$23.88 million, -20.99% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price target is $31.33, which is an increase of 103.44% from the latest price.
News
MediWound Earnings release: Q1 2026
MediWound released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
MediWound reports Q1 EPS (23c), consensus (66c)
Reports Q1 revenue $1.48M, consensus $3.37M. “During the first quarter, we continued to advance both our strategic and operational priorities,” said Ofer Gonen, CEO of MediWound (MDWD). “Enrollment co...
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue ...
MediWound Slides: Corporate presentation
MediWound has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
MediWound to Report First Quarter 2026 Financial Results
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive bi...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support o...
MediWound says Vericel awarded ten-year contract valued at up to $197M
MediWound (MDWD) announced that Vericel (VCEL), its exclusive distributor of NexoBrid in North America, has been awarded a ten-year contract valued at up to $197M by the U.S. Biomedical Advanced…
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
MediWound management to meet with Maxim
Meeting to be held on March 17-18 hosted by Maxim.
MediWound Files Annual Report on Form 20-F
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announce...
MediWound Earnings Call Transcript: Q4 2025
2025 saw major clinical and manufacturing milestones, with EscharEx and NexoBrid advancing and revenue guidance reaffirmed for 2026–2028. Despite lower 2025 revenue due to US government delays, the balance sheet was strengthened and long-term growth drivers remain intact.
MediWound Annual report: Q4 2025
MediWound has published its Q4 2025 annual report on March 5, 2026.
MediWound Earnings release: Q4 2025
MediWound released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
MediWound reports Q4 EPS (56c), consensus (61c)
Reports Q4 revenue $1.867M, consensus $2.09M. “We entered 2026 with two strategic growth drivers,” said Ofer Gonen, Chief Executive Officer of MediWound (MDWD). “Our Phase III VALUE trial of EscharEx…
MediWound sees FY26 revenue $24M-$26M, consensus $26.21M
The Company reaffirms its revenue guidance of $24-26 million for 2026.
MediWound sees FY27 revenue $32M-$35M, sees FY28 revenue $50M-$55M
The Company reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028. Guidance assumes continued support from BARDA and the U.S. Department…
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational ; regulatory approvals expected in 2026 $17 million revenue in 2025 ; $54 million in cash a...
MediWound management to meet with Maxim
Meeting to be held on March 11-12 hosted by Maxim.
MediWound Slides: Corporate presentation
MediWound has posted slides in relation to its latest quarterly earnings report, which was published on March 3, 2026.
MediWound Transcript: TD Cowen 46th Annual Health Care Conference
NexoBrid is expanding capacity for global burn care markets, while EscharEx is advancing through late-stage trials targeting chronic wounds, with significant clinical advantages over competitors and projected peak U.S. sales of $831 million. Key milestones in 2024 include manufacturing expansion and phase III interim results for EscharEx.
MediWound Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
A late-stage biologic firm highlighted strong commercial growth for its burn therapy and advanced progress for its chronic wound asset, supported by robust financials and government partnerships. Key catalysts include manufacturing expansion, regulatory milestones, and a pivotal Phase III readout for EscharEx by late 2026.
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- Med...
MediWound to Present at Upcoming Investor Conferences
MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17 , 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t...
MediWound sees FY25 revenue $17M, consensus $22.98M
MediWound (MDWD) provided a corporate and financial update ahead of its participation in the J.P. Morgan Healthcare Conference. “As we enter 2026, we are encouraged by the momentum we’ve built…